Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product
Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B. Ford thinks the overall optimism around Abbott is because of the company’s promising product pipeline, particularly a new over-the-counter product called Lingo. Lingo: A potential game-changer Lingo